Intrepida Bio

Intrepida Bio, Inc. is a preclinical biotechnology company (founded 2019, headquartered in Encinitas / San Diego, CA) developing medicines that modulate the innate immune system to fight cancer and other diseases. Working with Biouniversa s.r.l., the company holds worldwide rights to develop proprietary monoclonal antibodies against the novel targets BAG3 and its receptor IFITM-2 — a signaling axis tumors hijack to build a growth-promoting, immune-evasive microenvironment (notably in pancreatic ductal adenocarcinoma, PDAC). Intrepida raised roughly $9.5M from Canaan, Sofinnova, Indaco Venture Partners and Vertis to fund IND-enabling studies of its lead oncology program. It was surfaced as a portfolio company of canaan-partners and added to the API Evangelist network as a stub. NOTE: this is a therapeutics/drug-discovery company with no public API, developer portal, or software product surface; its website (intrepidabio.com) no longer resolves and the entity appears dormant/defunct, so no API artifacts apply.

Intrepida Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Oncology, Immuno-oncology, and Innate Immunity.

🌐 Visit website 📡 Source on GitHub
6.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyOncologyImmuno-oncologyInnate ImmunityMonoclonal AntibodiesCancerDrug DiscoveryPreclinicalTherapeutics

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 6.8/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.0 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/intrepedia-bio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

apis.yml Raw ↑ 
aid: intrepedia-bio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/intrepedia-bio.png
name: Intrepida Bio
description: 'Intrepida Bio, Inc. is a preclinical biotechnology company (founded 2019, headquartered in Encinitas / San Diego,
  CA) developing medicines that modulate the innate immune system to fight cancer and other diseases. Working with Biouniversa
  s.r.l., the company holds worldwide rights to develop proprietary monoclonal antibodies against the novel targets BAG3 and
  its receptor IFITM-2 — a signaling axis tumors hijack to build a growth-promoting, immune-evasive microenvironment (notably
  in pancreatic ductal adenocarcinoma, PDAC). Intrepida raised roughly $9.5M from Canaan, Sofinnova, Indaco Venture Partners
  and Vertis to fund IND-enabling studies of its lead oncology program. It was surfaced as a portfolio company of canaan-partners
  and added to the API Evangelist network as a stub. NOTE: this is a therapeutics/drug-discovery company with no public API,
  developer portal, or software product surface; its website (intrepidabio.com) no longer resolves and the entity appears
  dormant/defunct, so no API artifacts apply.'
url: https://raw.githubusercontent.com/api-evangelist/intrepedia-bio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-industry: Biotechnology
x-sub-industry: Immuno-oncology
x-founded: '2019'
x-headquarters: Encinitas, San Diego, CA, USA
x-founders:
- Joel F. Martin, Ph.D. (President & CEO)
- Olivier Laurent, Ph.D. (Chief Scientific Officer)
x-technology-targets:
- BAG3
- IFITM-2
x-investors:
- Canaan Partners
- Sofinnova Investments
- Indaco Venture Partners SGR
- Vertis
x-funding-raised: $9.5M
x-website: http://www.intrepidabio.com
x-website-status: unresolved (no DNS / registry "No match" as of 2026-07-19)
x-entity-status: dormant/defunct
x-has-api: false
x-enrichment-note: Enrichment pipeline ran 2026-07-19. No developer/API surface exists (biotech therapeutics company, website
  offline), so no OpenAPI, MCP, well-known, packages, or security artifacts could be searched, generated, or derived. Only
  the apis.yml identity pass was completed from public research (Canaan, Fierce Biotech, BioSpace, GlobeNewswire).
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Oncology
- Immuno-oncology
- Innate Immunity
- Monoclonal Antibodies
- Cancer
- Drug Discovery
- Preclinical
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence